NCT07376564 is a NA clinical trial of Low dose theacrine in Hemodynamic Measure, sponsored by Titch Madzima.

Who is sponsoring NCT07376564?

NCT07376564 is sponsored by Titch Madzima.

What drugs are being tested in NCT07376564?

Interventions in NCT07376564: Maltodextrin (Placebo), Low dose theacrine, Medium dose theacrine, High dose theacrine.

What condition does NCT07376564 study?

NCT07376564 studies Hemodynamic Measure, Cognitive Performance in Healthy Volunteers.

Is NCT07376564 still recruiting?

NCT07376564 is currently completed. Last updated 29 January 2026.

Last reviewed 2026-01-29 · How we verify

NCT07376564

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Assessing the Impact of High Theacrine Doses on Hemodynamic Measures

Completed NA Last updated 29 January 2026

What this trial tests

NA trial testing Maltodextrin (Placebo) in Hemodynamic Measure in 19 participants. Completed in 1 November 2024.

Timeline

9 August 2023

Primary endpoint
27 September 2024

1 November 2024

Quick facts

Lead sponsor	Titch Madzima
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	other
Enrollment	19
Start date	9 August 2023
Primary completion	27 September 2024
Estimated completion	1 November 2024
Sites	1 location across United States

Drugs / interventions tested

Maltodextrin (Placebo) — full drug profile →
Low dose theacrine
Medium dose theacrine
High dose theacrine

Conditions studied

Hemodynamic Measure — all drugs for Hemodynamic Measure →
Cognitive Performance in Healthy Volunteers — all drugs for Cognitive Performance in Healthy Volunteers →

Sponsor

Titch Madzima

Who can join

Adults 18 to 40, any sex, with Hemodynamic Measure or Cognitive Performance in Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project measured physiological and cognitive variables to determine the effectiveness of Theacrine (TCR) as a stimulant at doses greater than those previously tested. The study will be the first TCR study to use doses relative to body weight and will investigate impacts on regular caffeine consumers. A secondary aim of the study is to determine the impact of acute TCR supplementation on salivary cortisol and sAA, two physiological measures of stress and sympathetic nervous system activation. The findings of the study will provide new insight into the effects of higher TCR dosages, contributing to the analysis of TCR as a caffeine alternative for individuals with hypertension, tachycardia, or healthy caffeine consumers wanting to avoid a stimulant with adverse or habitual effects

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Assessing the impact of high theacrine doses on hemodynamic measures, cognitive performance, and physiological stress.
Stoke C, Chandler M, Madzima T. · · 2026 · PMID 41950524 · DOI 10.1139/apnm-2025-0380

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07376564 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Titch Madzima
Last refreshed: 29 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07376564.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing